Dr. Mark Basik, MDCM, FRCS(C)
Guerrera Family Cancer Scientist
Associate Professor of Surgery and Oncology
Medical Director, Breast Inter-disciplinary Team
Segal Cancer Center
Lady Davis Institute
Guerrera Family Cancer Scientist
Associate Professor of Surgery and Oncology
Medical Director, Breast Inter-disciplinary Team
Segal Cancer Center
Lady Davis Institute
Dr Basik is an Associate Professor in the Departments of Surgery and Oncology, McGill University and the Guerrera Family Cancer Scientist at the Segal Cancer Center. He is the director of the Cancer
Genomics and Translational Research Laboratory at the Lady Davis Institute for Medical Research, associated with the Jewish General Hospital. A McGill medical graduate, he trained as a general surgeon before completing a 4-year fellowship in surgical oncology (cancer surgery) at Roswell Park Cancer Institute.
He also was a visiting investigator at the National Human Genome Research Institute to pursue his studies on the genomics of breast and colon cancer. He came back to Montreal in September of 2003, to carry out basic cancer research at the Lady Davis Institute for Medical Research and to practice breast surgery at the Jewish General Hospital.
His laboratory studies the mechanisms of drug resistance in breast cancer using genomics tools. He also works on the discovery and validation of novel biomarkers in breast cancer. His laboratory has been funded by CIHR, CSSRI, Genome Quebec, the Cancer Research Society and the Quebec Breast Cancer Foundation.
Since 2008, he is a member of the Executive Committee of the CCTG¹s Breast Site Executive Committee and is a member of the Breast Working Group of the NSABP/NRG since 2010. He was recently elected to be co-chair of the NCI¹s Breast Oncology Local Disease (BOLD) task force.
Clinical Associate Professor of Medicine
University of British Columbia,
BC Cancer Agency, Vancouver Island Centre
Dr. Vanessa Bernstein is a medical oncologist at the Vancouver Island Cancer Centre who specializes in breast cancer and melanoma. She graduated magnum cum laude with a Bachelor of Arts from Dartmouth College, New Hampshire. She completed her MD, Internal Medicine and Medical Oncology training at the University of British Columbia. She was the 2000 Canadian Breast Cancer Foundation BC/Yukon Chapter Research Fellow. She used this opportunity to complete a Master’s of Science in Clinical Epidemiology from the Harvard School of Public Health.
Dr. Bernstein is the medical director of the Systemic Therapy Clinical Trials Unit at the Vancouver Island Cancer Centre. She has been a local and provincial principal investigator for many phase I, II and III clinical trials. She chaired the BC Cancer Agency Breast Cancer Systemic Policy Group from 2013-2015.
She is a Clinical Associate Professor of Medicine at the University of British Columbia and has taught many medical students and residents.
BCCA, Vancouver Clinic
Associate Professor of Medicine,
Department of Medicine,
University of British Columbia,
Chair British Columbia Breast Tumour Group
Stephen K. Chia, M.D., F.R.C.P. (Canada) is an Associate Professor of Medicine, Department of Medicine at the University of British Columbia, Vancouver, Canada. He also is a staff oncologist with the British Columbia Cancer Agency (BCCA), Vancouver, Canada. In addition, Dr. Chia serves as Chair for the British Columbia Breast Tumour Group and is physician coordinator for both the breast cancer and head and neck cancer clinical trials at the BCCA – Vancouver Cancer Centre. He currently sits on the NCIC Clinical Trials Committee Executive, NCIC CTG Breast Executive, NCIC CTG Breast Correlative Science Committee, as well as being a member of the ASCO Scientific Committee (2009-2012). He was a Breast Track chair (Triple Negative/Cytotoxic/Local) for the ASCO 2011 Annual Meeting. He is an active researcher in phase I-III trials in breast cancer, head and neck cancer and investigational new drugs. He has a real interest in neoadjuvant systemic therapy for breast cancer and drug development, as well as the field of translation research of predictive biomarkers/assays.
Dr. Chia has been widely published (over 70 peer reviewed publications) in international peer-reviewed journals including New England Journal of Medicine, Journal of Clinical Oncology, Lancet, Journal of the National Cancer Institute, Cell, Annals of Oncology and Clinical Cancer Research. Recently he has written the Commentaries in the Lancet and Lancet Oncology for the latest EBCTCG Overview (2011), NOAH study (2010) and the GEPARQUINTTO study (2012) respectively. An active researcher, he is currently carrying out clinical and translational studies in breast cancer with peer reviewed grant funded research from the National Cancer Institute of Canada, National Institute of Health (USA), Canadian Breast Cancer Research Alliance and Canadian Breast Cancer Foundation – British Columbia/Yukon Chapter.
He received his bachelor’s degree in Pharmacology from the University of British Columbia, where he also earned his medical degree in 1993. He obtained his Internal Medicine Fellowship and Medical Oncology Fellowship also from the University of British Columbia. Dr. Chia then completed post-fellowship training from 1999-2000 with the Dept. of Advanced Therapeutics – British Cancer Research Centre and at the Institute of Molecular Medicine with the University of Oxford.
Medical Oncologist, CancerCare Manitoba
University of Manitoba
Dr. Grenier is a medical oncologist and a clinical investigator at CancerCare Manitoba and she holds academic appointments in the Department of Medicine, Section of Medical Oncology and Hematology at the University of Manitoba. Her main areas of interest are breast and skin cancers and she was the past Chair of the CancerCare Manitoba Breast Cancer Disease Site Group.
Dr. Grenier was the Program Director for the Medical Oncology Training Program at the University of Manitoba up until July 2016 and the previous Chair of the Medical Oncology Examination Board of the Royal College of Physicians and Surgeons of Canada. She is a member of the Medical Oncology Specialty Committee of the Royal College and has been actively involved in the development and implementation of the Competency Based Education Curriculum for Canadian Medical Oncology Training Programs.
Her research interests include identifying and characterizing cardiotoxicity of cancer therapies and risk factors for breast cancer. She is also involved in determining ways of effectively communicating with cancer patients by means of decision aids and audiotapes. She has been the site principal investigator of multiple phase III breast cancer trials and the local representative for national and international clinical trial co-operative groups, including CCTG and the NRG. She is the current Co-chair of the Locally Advanced Breast Cancer Canadian National Consensus group, and has a research interest in the area of neoadjuvant therapy for breast cancer.
Associate Professor of Medicine
Division of Hematology/ Oncology
UCLA David Geffen School of Medicine, University of California
Los Angeles, CA
Dr Finn is an Associate Professor of Medicine in the Division of Hematology/ Oncology at the UCLA David Geffen School of Medicine and Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA.
He currently splits his time between patient care and laboratory and clinical research. His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer. Dr Finn has served as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatocellular cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics. His work has been published in journals such as the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Hepatology, Cancer Cell and elsewhere; Dr Finn has also given oral presentations at major meetings including American Society of Clinical Oncology (ASCO), European Cancer Conference (ECCO), and the American Association of Cancer Research (AACR) and others. Most recently, he has led the approval of palbociclib (Ibrance), the first CDK 4/6 inhibitor in cancer medicine, from pre-clinical development to global registration.
Dr Finn is a member of ASCO, American Association of Cancer Research (AACR). He is on the editorial boards of Clinical Cancer Research and Breast Cancer Research.
Hematologist and Medical Oncologist
Burnaby Hospital Regional Cancer Center
Director, BC Community Oncology Trialists
Dr. Wendy Lam is a hematologist and medical oncologist at the Burnaby Hospital Regional Cancer Centre.
She received her B.Sc (Pharmacy) at Dalhousie University and her MD from University of British Columbia. She then completed her Internal Medicine residency at UBC and Hematology fellowship at McMaster University.
She is the Founding Director of the British Columbia Community Oncology Trialists (BC Cot), which is a collaborative group of oncologists and hematologists involved in clinical research.
Her other interests include education of patients through meeting with patient groups. She has also been instrumental in organizing meetings for continued medical education.
She is Director of the Society of Hematology and Oncology of BC at British Columbia Medical Association
Professor of Pathology and Laboratory Medicine
Associate Member, Department of Orthopaedics
University of British Columbia
Chair, Sarcoma Disease Site Committee
Canadian Cancer Trials Group
Torsten O. Nielsen is a Professor of Pathology and Laboratory Medicine at the University of British Columbia. After completing the combined MD/PhD program at McGill, he undertook training at UBC, ICRF London, Stanford, the Cleveland Clinic and the Royal Orthopaedic before taking a position as a clinician-scientist pathologist, specializing in breast cancer and sarcomas. In breast cancer, he has worked extensively with the Breast Cancer Clinical Outcomes Group of the BC Cancer Agency to characterize the clinical features of the major intrinsic subtypes — Luminal A, Luminal B, HER2E and Basal, publishing multiple well-cited studies applying biomarkers onto large tissue microarray series. In doing so, he has worked to improve and standardize immunohistochemical tests for estrogen receptor, basal biomarkers, immune biomarkers and Ki67, leading a dedicated international consortium. With funding from the NIH Strategic Partnering to Evaluate Cancer Signatures, Dr. Nielsen worked with Drs. Chuck Perou, Matthew Ellis and Phil Bernard to develop breast cancer intrinsic subtyping research into the PAM50 test, now available on the NanoString platform as the Prosigna clinical assay for breast cancer subtype and risk. His subsequent work has applied genomic techologies to Canadian and European clinical trial series to assess the value of expression patterns and mutations. His other contributions include the world’s first large scale microarray studies of sarcomas, development of the DOG-1, TLE and beta-catenin biomarkers, identification of the biology driving tenosynovial giant cell tumors, synovial sarcoma and epithelioid sarcoma, and involvement in clinical trials of targeted therapies for these tumor types. Dr. Nielsen serves as scientific chair for the Breast Correlative Science and the Sarcoma Disease Site committees for the Canadian Cancer Trials Group, and is the Associate Director of the MD/PhD program for the University of British Columbia.
Medical Oncologist, Department of Medicine, Tom Baker Cancer Centre
Professor, Department of Medicine and Oncology
University of Calgary
Professor Paterson trained at Edinburgh Medical School and in London (St Bartholomew’s Hospital and Royal Marsden). He has completed clinical research in melanoma and gynecological malignancies; phase I/II and III clinical trials research in breast cancer; research on natural history of breast cancer; and established and novel prognostic factors in breast cancer; patho-physiology and treatment of bone metastases; malignant hypercalcemia and its treatment; and prevention of bone metastases with bisphosphonates.
He has also performed clinical research in palliative care medicine, prevention and treatment trials in breast cancer (with US based NSABP) and previously, research in autologous bone marrow transplantation. Tumor imaging radio-pharmaceuticals have also been |included in his fields of research.
He is on the Board of Directors of the NSABP and is Chair of NSABP B34 protocol and a Co-chair of the SWOG/NSABP intergroup bone metastasis prevention trial. He was Chair of the Alberta Breast Cancer Programme 2002-2010 and is Chair of the Health Canada Oncology Therapies Scientific Advisory Committee.
He is a clinical oncologist at the Tom Baker Cancer Centre and University of Calgary with a full-time practice mainly in patients with carcinoma of the breast. He teaches in the Physical Examination Course to medical students in the University of Calgary and writes a column for Alberta Doctors’ Digest on general topics.
Centre for Experimental Cancer Medicine,
Barts Cancer Institute
Professor Peter Schmid was appointed as Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London, in 2013. He is Clinical Director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. Professor Schmid is also Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre. He leads the academic breast cancer programmes and the cancer immune therapy group at Barts Cancer Institute.
Professor Schmid trained in medicine at Ludwig-Maximilians-University Munich, Technical University of Munich and University of Aberdeen. He was awarded scholarships by the ‘Studienstiftung des deutschen Volkes’, the ‘Hanns-Seidel-Foundation’, and the ‘Deutscher Akademischer Austauschdienst’. Professor Schmid completed a MD on mitochondrial creatine kinase at the Technical University Munich. He subsequently trained at the University Hospital Charité in Berlin in internal medicine, haematology and oncology, where he became head of breast cancer research and the phase I programme. He completed his PhD at the Charité University in Berlin in 2005 and was awarded the “habilitation and venia legendi” and an external readership by the Charité University in 2006. From 2005-2010, Prof. Schmid was a Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. In 2010, he was appointed as Foundation Chair in Cancer Medicine at the University of Sussex, and he was Director of the Clinical Investigation and Research Unit at Brighton and Sussex University Hospitals until his move to Barts.
Professor Schmid’s specialist cancer interests are breast and lung cancer, cancer immune therapy and early drug development. His research interests lie in stratified cancer medicine utilising novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. Professor Schmid has successfully led more than 20 national/international academic clinical studies, ranging from phase I to III, and several translational research programmes. He leads a collaborative group to establish circulating tumour DNA as a biomarker and is principal investigator of 2 ongoing, prospective international biomarker studies on predictive epigenetics from circulating tumour DNA.
Professor Schmid is a member of several national and international cancer organizations and research groups and has been involved in international consensus meetings on the management of breast cancer. Professor Schmid is a member of ESMO breast cancer Faculty, the UK NCRN breast cancer study group and of the breast cancer and translational research steering groups of the German cooperative group of medical oncology. He has authored or –co-authored 165 publications and has published a book on the management of bone metastases (3rd edition).
British Columbia Cancer Agency,
Dr. Christine Simmons is a Medical Oncologist at the BCCA Vancouver. She completed her residency training in Toronto, and completed a fellowship in Locally Advanced Breast Cancer at Princess Margaret Hospital in Toronto. She also completed a Master’s in Clinical Epidemiology at University of Toronto. She is a Clinical Assistant Professor at the University of British Columbia in the Faculty of Medicine. She is past Chair of the Locally Advanced Breast Cancer Canadian National Consensus group, and has a strong research interest in the area of neoadjuvant therapy for breast cancer. In July 2014 she took on the role of Clinical Skills Course Director in the undergraduate medical program at UBC.
Co-Medical Director, Hereditary Cancer Program
Chair, Breast Systemic Policy
BC Cancer Agency, Vancouver Centre
Dr. Sun is a medical oncologist at the BC Cancer Agency where she is chair of the provincial Breast Systemic Policy group, and Co-Medical Director of the Hereditary Cancer Program. She received her master’s degree in Cancer Genetics at McGill University and completed medical school at the University of Toronto. She is a graduate of the University of Calgary and University of British Columbia specialty training programs, and she completed her fellowship training in Translational Research in Thoracic Oncology at the University of Texas Southwestern. Dr. Sun’s clinical and research interests include cancer genetics, precision oncology, and clinical trials, with a focus on breast and thoracic malignancies.
Medical Director, Clinical Trials Unit
BC Cancer – Centre for the Southern Interior
Dr. Sara Taylor is a Medical Oncologist at BC Cancer in Kelowna, BC. She completed her medical degree at McGill University in Montreal, QC, and residency training at Queen’s Universtity in Kingston, ON. She then completed a fellowship in breast cancer and drug development at Princess Margaret Hospital and the Odette Cancer Centre at Sunnybrook Hospital in Toronto, ON. She is a Clinical Assistant Professor at the University of British Columbia Faculty of Medicine. She is the Medical Director of the Clinical Trials Unit at the Centre for the Southern Interior where she is actively involved in a number of phase I, II and II clinical trials.
Medical Director, Tom Baker Cancer Centre
Professor and Head, Department of Oncology
Cumming School of Medicine, University of Calgary
Department Head, Clinical Department of Oncology, Calgary Zone
CancerControl Alberta, Alberta Health Services
Medical Lead, Calgary Cancer Project
Dr. Sunil Verma is a Professor and Head of the Department of Oncology at the University of Calgary. He is also the Medical Director of the Tom Baker Cancer Centre. He completed his medical degree and postgraduate training in internal medicine and medical oncology at the University of Alberta in Canada. Dr. Verma also completed a fellowship in breast cancer at the University of Toronto and a Masters degree in Medical Education at the University of Southern California.
Dr. Verma is internationally recognized for his research and education leadership in breast cancer. His research interests include developing novel therapies for breast cancer, reducing toxicities associated with systemic treatment and medical education. He is the principal investigator for many trials in breast cancer including a number of practice changing Phase III trials in breast cancer. His work has been published in the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology and Cancer. He has led and created numerous innovative educational projects in oncology and has won several teaching and mentoring awards.
Clinical Assistant Professor, University of British Columbia
Director of Breast Radiation Oncology, BCCA
David Voduc has been a radiation oncologist at the BC Cancer Agency since 2006. His clinical focus is breast and gastrointestinal oncology. David Voduc completed a research fellowship in molecular epidemiology at the Genetic Pathology Evaluation Centre at the University of British Columbia. His research has focused primarily on breast cancer subtyping using immunohistochemistry, and using novel immunohistochemical biomarkers to improve clinical decision-making. Applying this knowledge to the clinic will hopefully lead to more selective use of adjuvant therapies, improved survival outcomes, and reduced treatment-related morbidity. David Voduc is also a member of the Breast Cancer Outcomes Unit and is the current chair of the collaborative GPEC-BCOU group (www.gpec.ubc.ca). He is currently head of the breast radiation oncology group in Vancouver.